A Phase 3 Study of I-Metaiodobenzylguanidine or Crizotinib Added to Intensive Therapy for Children with Newly Diagnosed High-Risk Neuroblastoma (NBL) (IND# 134379)

Go Back to All Clinical Trials

A Phase 3 Study of I-Metaiodobenzylguanidine or Crizotinib Added to Intensive Therapy for Children with Newly Diagnosed High-Risk Neuroblastoma (NBL) (IND# 134379)

Brief description of study

?The primary purpose of the study is to assess the effectiveness and safety of targeted radiopharmaceutical therapy with 131I-MIBG or crizotinib for patients with high-risk neuroblastoma. We want to know if the treatment can eliminate chemotherapy in patients likely cured with surgery alone and reduce toxicity for those need to undergo chemotherapy.

Clinical Study Identifier: s18-01766

ClinicalTrials.gov Identifier: NCT03067181

Principal Investigator: Chana Glasser.

Other Investigators: Joshua Isao Chan, Lia Phillips, Christeen Azmy, Sylwia Jasinski.

Contact the research team to learn more about this study.

Your Email

Not a valid e-mail address

Please Provide Email Address

First Name

First name is mandatory

Last Name

Your Phone

Please provide phone number

Invalid phone number

Valid phone number

Comments

Send Confirmation of This To Me

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Perlmutter Cancer Center

Clinical Trials & Research Studies